You have 9 free searches left this month | to do more
Showing 1 - 25 of
279 items
Did you mean:
Trials Per Page
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
N
MAP to Provide Access to Ruxolitinib, for Patients With PMF or PPV MF or PET-MF
Available
  • Primary Myelofibrosis (PMF)
  • +2 more
  • (no location specified)
2022-01-18
Jan 18, 2022
S
Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) - 2017
Completed
Has Results
  • Primary Myelofibrosis (PMF)
  • +2 more
  • Phoenix, Arizona
  • +12 more
2021-01-12
Jan 12, 2021
S
A Safety and Tolerability Study of Jaktinib
Not yet recruiting
  • Myelofibrosis
  • Jaktinib Hydrochloride Tablet
  • (no location specified)
2022-03-03
Mar 3, 2022
S
Jaktinib Hydrochloride for the Treatment of Ruxolitinib Intolerance of Myelofibrosis
Recruiting
  • Myelofibrosis
  • +3 more
  • Jaktinib hydrochloride tablets
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital of Medical School of Zhejiang Univ
2021-06-11
Jun 11, 2021
I
IMG-7289 in Patients With Myelofibrosis - 2022
Completed
  • Myelofibrosis
  • +3 more
  • Ann Arbor, Michigan
  • +4 more
2022-03-28
Mar 28, 2022
S
Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib
Recruiting
  • Primary Myelofibrosis (PMF)
  • +2 more
  • Larkspur, California
  • +2 more
2021-09-21
Sep 21, 2021
P
Clinical Trial of Aplidin® in Patients With Primary Myelofibrosis - 2011
Completed
Has Results
  • Myelofibrosis
  • APLIDIN (plitidepsin)
  • Rochester, Minnesota
  • +1 more
2020-09-17
Sep 17, 2020
H
18F-FLT (PET/CT) in Prefibrotic/Early Primary Myelofibrosis and Essential Thrombocythemia
Unknown status
  • Essential Thrombocythemia
  • +2 more
  • Diagnostic (18F-FLT PET/CT)
  • Doha, Qatar
    National Center for Cancer Care & Research (NCCCR)
2020-09-27
Sep 27, 2020
L
A Study of LNK01002 in Patients With Primary (PMF) or Secondary Myelofibrosis (PV-MF, ET-MF) or Acute Myeloid Leukemia
Recruiting
  • Acute Myeloid Leukemia
  • +3 more
  • Farmington Hills, Michigan
  • +1 more
2021-06-05
Jun 5, 2021
K
Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis
Recruiting
  • Primary Myelofibrosis (PMF)
  • +2 more
  • Glendale, California
  • +22 more
2021-10-30
Oct 30, 2021
S
Extended Access of Momelotinib in Adults With Myelofibrosis
Enrolling by invitation
  • Post-polycythemia Vera Myelofibrosis (Post-PV MF)
  • +2 more
  • Orange, California
  • +91 more
2022-03-07
Mar 7, 2022
S
Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF - 2019
Completed
  • Primary Myelofibrosis (PMF)
  • +2 more
  • Los Angeles, California
  • +47 more
2020-04-01
Apr 1, 2020
S
Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis - 2019
Completed
  • Primary Myelofibrosis
  • +2 more
  • Phoenix, Arizona
  • +113 more
2020-04-13
Apr 13, 2020
S
Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET) - 2012
Completed
  • Primary Myelofibrosis
  • +2 more
  • Stanford, California
  • +5 more
2019-01-30
Jan 30, 2019
S
Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET) - 2014
Completed
  • Primary Myelofibrosis
  • +2 more
  • Stanford, California
  • +5 more
2019-01-31
Jan 31, 2019
I
Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis - 2017
Completed
Has Results
  • Myelofibrosis
  • +2 more
  • Rochester, Minnesota
  • +1 more
2018-02-13
Feb 13, 2018
K
KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment
Recruiting
  • Primary Myelofibrosis (PMF)
  • +2 more
  • Birmingham, Alabama
  • +116 more
2022-03-04
Mar 4, 2022
C
A Safety Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib With Concomitant Luspatercept for Subjects With Anemia
Recruiting
  • Primary Myelofibrosis
  • +2 more
  • Aurora, Colorado
  • +34 more
2022-02-16
Feb 16, 2022
C
An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib
Recruiting
  • Primary Myelofibrosis
  • +2 more
  • Darlinghurst, New South Wales, Australia
  • +109 more
2022-03-15
Mar 15, 2022
N
Study of Select Combinations in Adults With Myelofibrosis
Withdrawn
  • Primary Myelofibrosis
  • +4 more
  • (no location specified)
2021-03-02
Mar 2, 2021
I
A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis
Active, not recruiting
  • MPN (Myeloproliferative Neoplasms)
  • Birmingham, Alabama
  • +38 more
2022-04-05
Apr 5, 2022
C
A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
Recruiting
  • Primary Myelofibrosis
  • Aomori, Japan
  • +15 more
2022-01-19
Jan 19, 2022
F
Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis
Recruiting
  • Primary Myelofibrosis
  • Secondary Myelofibrosis
  • Allogeneic Hematopoietic Stem Cell Transplantation
  • +9 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2021-12-14
Dec 14, 2021
M
Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis
Recruiting
  • Myelofibrosis Transformation in Essential Thrombocythemia
  • +2 more
  • Elotuzumab
  • Questionnaire Administration
  • Houston, Texas
    M D Anderson Cancer Center
2021-02-17
Feb 17, 2021
C
A Clinical Trial of TQ05105 Tablets in the Treatment of Moderate and High Risk Myelofibrosis
Recruiting
  • Moderate and High Risk Myelofibrosis
  • TQ05105 tablets
  • Hydroxycarbamide tablets
  • Beijing, Beijing, China
  • +3 more
2021-11-23
Nov 23, 2021